On Monday, Alembic Pharmaceuticals saw a surge in its stock prices after the USFDA greenlit its Diltiazem Hydrochloride Tablets, a crucial treatment for high blood pressure and angina. This pivotal approval brings the company’s total USFDA ANDA approvals to an impressive 230, highlighting its strong position in the pharmaceutical market.
The information on this website does not constitute investment advice or a recommendation or a solicitation to engage in any investment activity. This website and its content are not intended for residents of the UAE, US, Canada, Australia, UK, Russia, North Korea, China, Japan, Hong Kong, Singapore and Iran.
Top10 International FZ LLE | 17th Floor, Creative Tower | 4422 | Fujairah | TRN: 100608946800003